Acquisition of IVERIC bio to gain a geographic atrophy treatment and ophthalmology platform
A standalone M&A transaction to strengthen the ophthalmology portfolio by acquiring IVERIC bio and gaining ophthalmology products, clinical development capabilities, and market access, including treatments for geographic atrophy.
Companies1How many companies write about this.
Threads1One company can carry more than one thread here.